Initializing

Gaining access to millions of annotated cells across 10+ cancer indications.

Analyzing pathology slides

Our algorithms detect and characterize tissue and cell architecture.

Calculating Features

Cell & area locations are intersected to compute over hundreds of complex feature values.

Predicting Response

Deep-learning models combining spatial features and clinical data drive the discovery of pathology based spatial biomarkers.

Initializing

Gaining access to millions of annotated cells across 10+ cancer indications.

Analyzing pathology slides

Our algorithms detect and characterize tissue and cell architecture.

Calculating Features

Cell & area locations are intersected to compute over hundreds of complex feature values.

Predicting Response

Deep-learning models combining spatial features and clinical data drive the discovery of pathology based spatial biomarkers.

PRODUCTS

Our Offering

ABOUT US

We are transforming precision medicine with AI-powered pathology

Our team’s work is a unique collaboration of experienced AI technologists, physicians and exceptional healthcare research professionals.

Exploratory Research Platform

Our Platform empowers researchers to discover novel, human interpretable pathology-based biomarkers that predict response to therapy, identify genomic markers or explain complex biological phenomena at scale.

AI-Powered Clinical Trial Assays

Qualified biomarkers are incorporated into prospective clinical trials via Nucleai’s AI-powered digital assays. In partnership with CROs and central laboratories, we support a compliant (FDA, CLIA, GxP) and scalable patient selection process.

Companion Diagnostics Development

In partnership with biopharma, diagnostics and clinical laboratories, we develop and deploy Nucleai’s digital assays as companion diagnostics across the world, providing physicians with the best diagnostic tools to improve patient lives.

Our Platform

Nucleai’s platform unlocks spatial insights. In Nucleai Atom, your pathology slides are transformed into raw data of cell and area locations. The raw data is fed into the Nucleai engine, computing hundreds of spatial features intersected with outcome to predict drug response.

DATA & INSTITUTIONAL PARTNERS

INVESTORS

SCIENTIFIC PUBLICATIONS

LEADERSHIP

CAREERS

Join Us in Biomarker Discovery

At Nucleai, we bring physicians and researchers cutting edge AI-based technology that identifies pathology-based biomarkers that can predict response to therapy and significantly improve patient outcomes. Come join our team of experienced AI engineers, world renowned clinicians, and others, to revolutionize precision medicine and make a major impact.
Associate Director of Translational Science

Associate Director of Translational Science

United States

Data Science Team Lead

Data Science Team Lead

Tel Aviv

DevOps Engineer

DevOps Engineer

Tel Aviv

Director Of Marketing

Director Of Marketing

United States

Medical Data Specialist Full Time

Medical Data Specialist Full Time

Tel Aviv

Researcher

Researcher

Tel Aviv

Senior Product Manager

Senior Product Manager

Tel Aviv

NEWS & UPDATES

Spatial Multiomics Powers Pathology Prediction

Spatial multiomics, still in its discovery phase, can mean different things to different people. It typically denotes the visualization of transcriptomic and proteomic data in the context of tissue architecture, either directly on the same section or on serial sections that are integrated computationally. Spatial multiomics may eventually grow to encompass lipids, glycans, metabolites, epigenetic […]

Read More

Nucleai Launches New Multiplex Imaging Spatial Analysis Solution to Increase Reliability and Speed of Immunofluorescence Analysis for Drug Discovery and Development

Nucleai, a leader in AI-powered spatial biology, today announced the expansion of its spatial biology platform to include a new generation of multiplex immunofluorescence (mIF) analysis that uses deep learning to establish new levels of accuracy, speed, and generalizability, further unlocking the power of mIF data for drug discovery and development. Nucleai will present new […]

Read More

Nucleai Hopes to Engage Pharma on Next-Gen Immunotherapies With Proof-of-Concept AI-Based Biomarker

NEW YORK –Nucleai researchers investigated whether, by using spatial biology to analyze interactions between the immune system and tumor microenvironment, it is possible to find biomarkers predictive of sensitivity to immuno-oncology drugs. In a retrospective multi-center study conducted in the US and Israel, where the firm is based, Nucleai analyzed biopsy slides and clinical outcomes […]

Read More

Israel: An Untapped Biotech Investment Opportunity

With military precision and academic ingenuity, Israel is building a thriving biotech ecosystem on the heels of a renowned high-tech industry. Much more than just the iconic Teva Pharmaceuticals, venture capitalists would do well to pay attention to the innovation stemming from this largely unmined investment opportunity. “Everything about it is about innovation,” said Michael […]

Read More

Add Your Heading Text Here